130 related articles for article (PubMed ID: 33565809)
41. Carcinomas associated with Lynch syndrome: a family history.
Pinar G; Ayhan A
Int Surg; 2011; 96(4):286-90. PubMed ID: 22808608
[TBL] [Abstract][Full Text] [Related]
42. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
Rousseau B; Foote MB; Maron SB; Diplas BH; Lu S; Argilés G; Cercek A; Diaz LA
N Engl J Med; 2021 Mar; 384(12):1168-1170. PubMed ID: 33761214
[No Abstract] [Full Text] [Related]
43. The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.
Dalgleish AG; Di Palma S; Nathan K; Powell B; Patel N; Fusi A
Eur J Cancer; 2019 May; 113():14-18. PubMed ID: 30954882
[No Abstract] [Full Text] [Related]
44. ["Second-look" in initially unresectable pancreatic adenocarcinoma after neoadjuvant chemotherapy].
Gómez García ME; Carbonell Castelló F; Alberola Soler A; Poves Gil PM; García Espinosa R
Cir Esp; 2013 Dec; 91(10):683-5. PubMed ID: 23498348
[No Abstract] [Full Text] [Related]
45. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression.
Kuan SF; Ren B; Brand R; Dudley B; Pai RK
Hum Pathol; 2017 May; 63():33-39. PubMed ID: 28232158
[TBL] [Abstract][Full Text] [Related]
47. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
[TBL] [Abstract][Full Text] [Related]
48. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
49. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
Adam MA; Paniccia A
Ann Surg Oncol; 2021 Jul; 28(7):3808-3809. PubMed ID: 33475885
[No Abstract] [Full Text] [Related]
50. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
[TBL] [Abstract][Full Text] [Related]
51. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.
Zlobec I; Molinari F; Kovac M; Bihl MP; Altermatt HJ; Diebold J; Frick H; Germer M; Horcic M; Montani M; Singer G; Yurtsever H; Zettl A; Terracciano L; Mazzucchelli L; Saletti P; Frattini M; Heinimann K; Lugli A
Br J Cancer; 2010 Jan; 102(1):151-61. PubMed ID: 19935791
[TBL] [Abstract][Full Text] [Related]
53. Extent of Pedigree Required to Screen for and Diagnose Hereditary Nonpolyposis Colorectal Cancer: Comparison of Simplified and Extended Pedigrees.
Heo Y; Kim MH; Kim DW; Lee SA; Bang S; Kim MJ; Oh HK; Kang SB; Kang SI; Park JW; Ryoo SB; Jeong SY; Park KJ
Dis Colon Rectum; 2020 Feb; 63(2):152-159. PubMed ID: 31842160
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
Ferriss JS; Williams-Brown MY
Curr Treat Options Oncol; 2019 Aug; 20(10):75. PubMed ID: 31444655
[TBL] [Abstract][Full Text] [Related]
55. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
[TBL] [Abstract][Full Text] [Related]
56. Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
Mans L; Pezzullo M; D'Haene N; Van de Stadt J; Van Laethem JL
Eur J Cancer; 2020 Aug; 135():75-77. PubMed ID: 32554216
[No Abstract] [Full Text] [Related]
57. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
[TBL] [Abstract][Full Text] [Related]
58. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
59. [New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].
Quesada S; Vaflard P
Bull Cancer; 2022 Feb; 109(2):111-113. PubMed ID: 34998526
[No Abstract] [Full Text] [Related]
60. Role of adjuvant therapy in the management of pancreatic cancer.
Laheru D; Yeo CJ
Adv Surg; 2005; 39():223-44. PubMed ID: 16250554
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]